Ipca Labs - Ipca Laboratories Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Ipca Labs - Ipca Laboratories Share Price

1,613.60-16.61 (-1.02%)

Closed
As On: 11 Jun, 2026, 03:54 PM IST
As On: 11 Jun, 2026, 03:41 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	1,630.20
High	1,642.00
Low	1,606.20
Prev Close	1,630.20
Volume	86,082
VWAP(₹)	1,623.14

Key Metrics

PE Ratio(x)	35.88
EPS - TTM(₹)	44.98
MCap(₹ Cr.)	40,937.71
MCap Rank	16
PB Ratio(x)	4.34
Div Yield(%)	0.37
Face Value(₹)	1.00
52W High(₹)	1,678.30
52W Low(₹)	1,251.60
MCap/Sales	4.22
Beta(1 Month)	0.64
BV/Share(₹)	375.40

Ipca Labs share price insights

Rank 263 - ET 5002025 ranking

Intraday fact check
In the last 21 years, only 1.73 % trading sessions saw intraday declines higher than 5 % .
ROE Outperforming 5 Year Average
Company delivered ROE of 14.15% in year ending Mar 31, 2026 outperforming its 5 year avg. of 11.57%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 22.39% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Ipca Labs Share Price Update
Ipca Laboratories Ltd. share price moved down by -1.02% from its previous close of Rs 1,630.20. Ipca Laboratories Ltd. stock last traded price is 1,613.60
Share Price Value
Today/Current/Last 1,613.601,621.60
Previous Day 1,630.201,634.25

Found Insights useful?

Ipca Labs Share Price Returns

1 Day	-1.02%
1 Month	5.12%
3 Months	5.2%
1 Year	16.14%
3 Years	121.66%
5 Years	57.67%

Ipca Labs Share Recommendations

Mean recosCurrent

BUY

14 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	7	7	7	7
Buy	5	5	5	5
Hold	2	2	2	2
Sell	-	-	-	-
Strong Sell	-	-	-	1
# Analysts	14	14	14	15

Recent Recos

Target₹1980
OrganizationMotilal Oswal Financial Services
BUY

Target₹1250
OrganizationPrabhudas Lilladher
REDUCE

Target₹1150
OrganizationPrabhudas Lilladher
REDUCE

View all Stock Recommendations

News & Analysis

View all Ipca Labs Share News & Announcements

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	2,482.22	2,412.69	2,584.36	2,341.51	2,272.51
Total Income Growth (%)	2.88	-6.64	10.37	3.04	0.31
Total Expenses	2,057.57	1,949.09	2,173.17	1,992.49	2,123.00
Total Expenses Growth (%)	5.57	-10.31	9.07	-6.15	12.88
EBIT	424.65	463.60	411.19	349.02	149.51
EBIT Growth (%)	-8.40	12.75	17.81	133.44	-61.14
Profit after Tax (PAT)	299.07	326.27	282.57	233.21	67.82
PAT Growth (%)	-8.34	15.47	21.17	243.87	-72.67
EBIT Margin (%)	17.11	19.22	15.91	14.91	6.58
Net Profit Margin (%)	12.05	13.52	10.93	9.96	2.98
Basic EPS (₹)	13.31	12.09	12.35	9.19	2.67

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	1,844.23	1,863.00	1,952.24	1,771.92	1,659.93
Total Income Growth (%)	-1.01	-4.57	10.18	6.75	-1.20
Total Expenses	1,483.90	1,436.27	1,532.47	1,403.11	1,626.58
Total Expenses Growth (%)	3.32	-6.28	9.22	-13.74	23.75
EBIT	360.33	426.73	419.77	368.81	33.35
EBIT Growth (%)	-15.56	1.66	13.82	1,005.88	-90.88
Profit after Tax (PAT)	262.29	303.45	304.74	262.04	-65.05
PAT Growth (%)	-13.56	-0.42	16.30	-	-124.31
EBIT Margin (%)	19.54	22.91	21.50	20.81	2.01
Net Profit Margin (%)	14.22	16.29	15.61	14.79	-3.92
Basic EPS (₹)	11.54	11.96	12.01	10.33	-2.56

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	9,820.78	9,032.39	7,829.81	6,369.94	5,896.36
Total Revenue Growth (%)	8.73	15.36	22.92	8.03	7.54
Total Expenses	8,161.83	7,696.20	6,879.39	5,624.65	4,760.64
Total Expenses Growth (%)	6.05	11.87	22.31	18.15	16.29
Profit after Tax (PAT)	1,141.12	737.68	547.35	471.32	884.08
PAT Growth (%)	54.69	34.77	16.13	-46.69	-22.45
Operating Profit Margin (%)	17.98	15.89	14.12	12.66	19.61
Net Profit Margin (%)	11.82	8.25	7.10	7.54	15.16
Basic EPS (₹)	46.94	35.14	25.82	18.58	34.85

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	7,431.39	6,749.21	6,277.75	5,925.81	5,455.49
Total Revenue Growth (%)	10.11	7.51	5.94	8.62	4.89
Total Expenses	5,868.84	5,467.90	5,322.23	5,175.32	4,367.13
Total Expenses Growth (%)	7.33	2.74	2.84	18.51	14.28
Profit after Tax (PAT)	1,132.52	650.76	530.41	505.70	870.94
PAT Growth (%)	74.03	22.69	4.89	-41.94	-23.65
Operating Profit Margin (%)	21.89	20.13	17.45	13.66	20.29
Net Profit Margin (%)	15.43	9.74	8.60	8.69	16.13
Basic EPS (₹)	45.84	36.75	26.16	19.93	34.33

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 22.39% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	12,370.19	11,760.55	11,101.28	8,626.43	7,638.86
Total Assets Growth (%)	5.18	5.94	28.69	12.93	25.88
Total Liabilities	2,846.13	3,372.28	3,374.28	2,711.11	2,069.97
Total Liabilities Growth (%)	-15.60	-0.06	24.46	30.97	53.08
Total Equity	9,524.06	8,388.27	7,727.00	5,915.32	5,568.89
Total Equity Growth (%)	13.54	8.56	30.63	6.22	18.08
Current Ratio (x)	2.76	2.63	2.35	2.87	3.04
Total Debt to Equity (x)	0.09	0.19	0.22	0.25	0.14
Contingent Liabilities	0.00	613.89	303.44	2,125.64	274.03

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	9,775.50	9,070.92	8,659.27	8,446.97	7,466.86
Total Assets Growth (%)	7.77	4.75	2.51	13.13	24.24
Total Liabilities	1,796.15	2,179.30	2,310.56	2,569.67	1,943.52
Total Liabilities Growth (%)	-17.58	-5.68	-10.08	32.22	54.57
Total Equity	7,979.35	6,891.62	6,348.71	5,877.30	5,523.34
Total Equity Growth (%)	15.78	8.55	8.02	6.41	16.21
Current Ratio (x)	2.82	2.69	2.31	2.91	3.13
Total Debt to Equity (x)	0.03	0.13	0.18	0.24	0.14
Contingent Liabilities	0.00	490.63	308.45	2,161.85	287.71

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	1,141.97	1,321.32	944.65	805.81	856.04
Net Cash used in Investing Activities	-246.77	-869.50	-1,291.79	-725.00	-855.05
Net Cash flow from Financing Activities	-753.53	-282.98	-552.55	507.24	426.81
Net Cash Flow	141.67	168.84	-823.19	588.05	431.92
Closing Cash & Cash Equivalent	1,066.30	924.63	755.79	1,578.98	990.93
Closing Cash & Cash Equivalent Growth (%)	15.32	22.34	-52.13	59.34	77.27
Total Debt/ CFO (x)	0.62	0.99	1.47	1.81	0.92

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	1,378.12	1,374.07	830.51	762.29	840.14
Net Cash used in Investing Activities	-696.99	-738.81	-1,355.18	-709.61	-823.89
Net Cash flow from Financing Activities	-745.21	-428.44	-464.88	506.38	426.10
Net Cash Flow	-64.08	206.82	-989.55	559.06	442.35
Closing Cash & Cash Equivalent	658.02	722.10	515.28	1,504.83	943.54
Closing Cash & Cash Equivalent Growth (%)	-8.87	40.14	-65.76	59.49	88.26
Total Debt/ CFO (x)	0.17	0.63	1.36	1.87	0.91

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 246.77 cr for investing activities which is an YoY decrease of 71.62%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	14.15	10.61	8.64	8.06	16.09
Return on Capital Employed (%)	17.23	15.15	12.44	11.59	18.52
Return on Assets (%)	9.22	6.27	4.93	5.46	11.57
Interest Coverage Ratio (x)	28.35	21.42	10.46	23.11	178.91
Asset Turnover Ratio (x)	0.80	0.78	0.78	0.77	0.80
Price to Earnings (x)	35.71	51.81	57.47	43.67	30.49
Price to Book (x)	5.04	5.48	4.96	3.52	4.90
EV/EBITDA (x)	19.63	22.26	23.45	19.23	19.73
EBITDA Margin (%)	22.31	20.34	18.76	16.85	23.59

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	14.19	9.44	8.35	8.60	15.76
Return on Capital Employed (%)	19.21	17.57	15.07	11.73	17.87
Return on Assets (%)	11.58	7.17	6.12	5.98	11.66
Interest Coverage Ratio (x)	43.09	25.32	10.96	23.29	180.26
Asset Turnover Ratio (x)	0.78	0.75	0.72	0.73	0.80
Price to Earnings (x)	35.97	58.82	59.52	40.82	30.96
Price to Book (x)	5.10	5.53	4.95	3.50	4.87
EV/EBITDA (x)	21.62	24.30	24.52	19.82	20.84
EBITDA Margin (%)	25.55	23.90	21.44	17.59	24.07

Insights

ROE Outperforming 5 Year Average
Company delivered ROE of 14.15% in year ending Mar 31, 2026 outperforming its 5 year avg. of 11.57%. (Source: Consolidated Financials)

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
45%
Positive Movement
since 1st Jan 2005
on basis
54%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 1652.40 Pivot
1636.70
S1 1614.50
R2 1674.60 S2 1598.80
R3 1712.50 S3 1560.90
Average True Range
5 Days 14 Days 28 Days
54.08 54.95 53.30

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Ipca Labs	35.88	4.30	14.15	17.23	9.22	15.36	17.98	12.35	46.94	2.76	0.09	0.62
Ajanta Pharma	37.19	8.68	23.32	29.40	17.15	13.41	25.56	19.36	84.53	2.64	0.05	0.40
Gland Pharma	36.99	3.67	9.91	13.96	8.21	20.18	23.67	15.97	62.35	4.68	0.02	0.24
J B Chemicals	50.98	8.70	17.05	22.50	14.27	9.92	23.74	17.10	45.16	4.92	0.00	0.00
Emcure Pharmaceuticals Ltd.	34.53	6.41	18.67	25.65	9.61	15.02	15.88	10.22	48.77	1.46	0.24	1.28
Add More

Annual Ratios (%)

Choose from Peers

Wockhardt
Piramal Pharma
OneSource Specialty
Eris Lifesciences
Syngene Int.

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Found Peer Comparison useful?

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 11,34,67,472 44.72 % 0.00
Pledge 0 0.00 % 0.00
FII 2,69,69,030 10.63 % 0.01
DII 9,41,89,589 37.12 % 0.13
MF 7,92,58,017 31.24 % 0.71
Others 1,90,78,127 7.53 % -0.14
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 44.72 44.72 44.72 44.72
Pledge 0.00 0.00 0.00 0.00
FII 10.63 10.62 10.42 10.67
DII 37.12 36.99 36.45 35.88
Mutual Funds 31.24 30.52 30.04 29.61
Others 7.53 7.67 8.40 8.72

Mutual Funds Ownership

MF Ownership as on 30 April 2026

HDFC Mid Cap Direct-G
Equity: Mid Cap
5
- 2,770.41
  Amount Invested (in Cr.)
- 2.92%
  % of AUM
- 0.57
  % Change (MoM basis)
Kotak Midcap Direct-G
Equity: Mid Cap
3
- 1,890.36
  Amount Invested (in Cr.)
- 2.97509844%
  % of AUM
- 2.86
  % Change (MoM basis)
Axis Midcap Direct-G
Equity: Mid Cap
2
- 613.19
  Amount Invested (in Cr.)
- 1.8998%
  % of AUM
- 5.54
  % Change (MoM basis)

View all Mutual Fund Schemes

Ipca Labs Top Searches

Corporate Actions

Recent
Final
600%
May 29, 2026
Board Meeting
Audited Results & Dividend
May 04, 2026
Board Meeting
Quarterly Results
Jan 22, 2026

Announced on	Meeting on
May 04, 2026	May 29, 2026
Audited Results & Dividend
Jan 22, 2026	Feb 13, 2026
Quarterly Results
Oct 17, 2025	Nov 13, 2025
Quarterly Results
Jul 24, 2025	Aug 11, 2025
Quarterly Results
May 14, 2025	May 29, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 29, 2025 Aug 05, 2025 200%
Oct 24, 2024 Nov 25, 2024 200%
May 29, 2024 Aug 06, 2024 200%
Oct 26, 2023 Nov 22, 2023 200%
May 29, 2026 - 600%
Bonus
Announced on Ex-Date
Oct 27, 2004 Jan 28, 2005
Bonus Ratio: 1 share(s) for every 1 shares held
Splits
Announced on Ex-Date
Nov 13, 2021 Jan 10, 2022
Split: Old FV2.0| New FV:1.0
Jan 21, 2010 Mar 22, 2010
Split: Old FV10.0| New FV:2.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
May 29, 2025 Aug 11, 2025
-
Jul 18, 2024 Aug 13, 2024
Book closure from Aug 7, 2024 to Aug 13, 2024
Feb 23, 2024 Mar 30, 2024
-
May 29, 2023 Aug 10, 2023
-
Feb 24, 2023 Mar 31, 2023
(Revised)

About Ipca Labs

Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 40,937.71 Crore) operating in Pharmaceuticals sector.

Ipca Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Scrap, Sale of services, Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 2,482.22 Crore, up 2.88 % from last quarter Total Income of Rs 2,412.69 Crore and up 9.23 % from last year same quarter Total Income of Rs 2,272.51 Crore. Company has reported net profit after tax of Rs 309.40 Crore in latest quarter.

The company’s top management includes Mr.Premchand Godha, Mr.Pranay Godha, Mr.Ajit Kumar Jain, Mr.Prashant Godha, Mr.Kamal Kishore Seth, Dr.Narendra Mairpady, Dr.(Ms.)Swati Patankar, Mr.Vivek Shiralkar, Mr.Harish P Kamath. Company has Natvarlal Vepari & Co. as its auditors. As on 31-03-2026, the company has a total of 25.37 Crore shares outstanding.

Ipca Labs Share Price Today is Rs. 1613.60. On previous day, the Ipca Labs Share Price (NSE) closed at Rs. 1634.0, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 44.72% of the stake in Ipca Labs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Ipca Labs stocks was 10.63% as compared to 10.62% in Dec 2025 with increase of 0.01%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 37.13% as compared to 36.99% in Dec 2025 with increase of 0.14%. Out of the total DII holdings in Ipca Labs shares 31.24% was held by mutual funds. The rest including public held is 7.52%. Ipca Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Ipca Labs Dividend: Ever since 1949, Ipca Labs dividends has been paid out around 50 times. As on 11 Jun, 2026, 03:54 PM IST, The overall dividend yield for Ipca Labs stands at 0.37%. The last dividend paid was on null (Rs. 6.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 44.98.

Ipca Labs Bonus: The most recent bonus issue had been in year January 28, 2005 around 21 years ago at 1 : 1 ratio. The first bonus issue was announced in Oct 2004.

Stock Forecast:
After showing 2482.22 Cr. of sales and 2.88% of quarterly net profit, there have been multiple ups and downs in the Ipca Labs stock prices in the past few weeks. For example, Ipca Labs stock price on 3rd of June 2026 was around Rs. 1554.7. Ipca Labs share price now stands at an average of Rs. 1613.60. Judging by last week's performance, stock is in up trend.

Ipca Labs has a median target price of Rs. 1707.0 in 12 months by 15 analysts. They have provided a high estimate of Rs. 1800.0 and low estimate of Rs. 1405.0 for Ipca Labs share.

Historical Prices and Performance:
Ipca Labs, incorporated in 1949 is a Mid Cap company (with a market cap of Rs. 41358.86) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Ipca Labs stock was 14.15%, 10.61%, 8.64%, 8.06% and 16.09% respectively.
The Ipca Labs share gave a 3 year return of 123.94% as compared to Nifty 50 which gave a return of 25.06%.
Ipca Labs announced 600.0% final dividend on null.

Key Metrics:
PE Ratio of Ipca Labs is 36.33
Prices/Sales Ratio of Ipca Labs is 4.22
Price/Book Ratio of Ipca Labs is 4.35

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Ipca Labs, major competitors and peers include Ajanta Pharma, Gland Pharma, J B Chemicals and Emcure Pharmaceuticals Ltd.. As of Dec 2025, the dividend yield of Ipca Labs stands at 0.37% while Ajanta Pharma, Gland Pharma, J B Chemicals and Emcure Pharmaceuticals Ltd. stand at 0.91%, 0.0%, 1.0% and 0.21% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 36.33 and 4.35 respectively.

Leadership of Ipca Labs :
Shailesh Laul is President - Operations (Formulations)
Pabitra Kumar Bhattacharya is President - Operations (API)
Shashil Mendonsa is President - International Marketing
Anil Pareek is President - Medical Affairs & Clinical Research
Sunil Ghai is President - Marketing
Harish P Kamath is Corporate Counsel & Company Secretary
Kavita Sehwani is President - Generics
Sanjay Kapadia is President - Corporate Quality Assurance
Ashok Kumar is President - R&D (Chemicals)
Premchand Godha is Executive Chairman
Ajit Kumar Jain is Managing Director & CFO
Pranay Godha is Managing Director & CEO
Prashant Godha is Executive Director
Swati Patankar is Independent Director
Narendra Mairpady is Independent Director
Vivek Shiralkar is Independent Director
Kamal Kishore Seth is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty 500, BSE 500, Nifty Pharma, BSE MidCap, BSE 250 LargeMidCap Index

Address

48, Kandivli Industrial Estate,Kandivli (West),Mumbai, Maharashtra - 400067

Contact

http://www.ipca.com

Executive Leadership

PG

Premchand Godha

Executive Chairman

PG

Pranay Godha

Managing Director & CEO

AK

Ajit Kumar Jain

Managing Director & CFO

PG

Prashant Godha

Executive Director

Show More

Auditors

Natvarlal Vepari & Co.

G M Kapadia & Co

FAQs about Ipca Labs share

1. What's the Ipca Labs share price today?
Ipca Labs share price is Rs 1,613.60 as on 11 Jun, 2026, 03:54 PM IST. Ipca Labs share price is down by 1.02% based on previous share price of Rs. 1634.0.
2. What is the PE & PB ratio of Ipca Labs?
The PE ratio of Ipca Labs stands at 36.24, while the PB ratio is 4.34.
3. What are the returns for Ipca Labs share?
Return Performance of Ipca Labs Shares:
- 1 Week: Ipca Labs share price moved down by 0.02%
4. What has been highest price of Ipca Labs share in last 52 weeks?
In last 52 weeks Ipca Labs share had a high price of Rs 1,678.30 and low price of Rs 1,251.60
5. What's the market capitalization of Ipca Labs?
Market Capitalization of Ipca Labs stock is Rs 40,937.71 Cr.

Top Gainers

As on 03:59 PM | 11 Jun 2026

Aegis Logistics

925.90

124.90 (15.60%)

111.45

8.52 (8.28%)

DOMS Industries

2,255.40

136.81 (6.46%)

Blue Jet Healthcare

498.45

28.70 (6.11%)

1,923.80

90.80 (4.96%)

Top Losers

As on 03:59 PM | 11 Jun 2026

Balkrishna Ind.

1,974.00

-109.20 (-5.25%)

1,133.10

-60.31 (-5.06%)

155.70

-7.93 (-4.85%)

166.91

-8.00 (-4.57%)

Adani Transmission

1,466.70

-68.90 (-4.49%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.